Fumihiko Sasai

Fumihiko Sasai

Auto-generated profile, based on publicly available information

Fumihiko Sasai

Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
PDF file
FPFederica Piani
Federica Piani
FSFumihiko Sasai
Fumihiko Sasai
PBPetter Bjornstad
Petter Bjornstad
Claudio  BorghiClaudio Borghi
Claudio Borghi
AYAshio Yoshimura
Ashio Yoshimura
Richard J JohnsonRichard J Johnson
Richard J Johnson
Hyperuricemia is common in chronic kidney disease (CKD) and may be present in 50% of patients presenting for dialysis. Hyperuricemia can be secondary to impaired glomerular filtration rate (GFR) that occurs in CKD. However, hyperuricemia can also precede the development of kidney disease and predict incident CKD. Experimental studies of hyperuricemic models have found that both soluble and crystalline uric acid can cause significant kidney damage, characterized by ischemia, tubulointerstitial fibrosis, and inflammation. However, most Mendelian randomization studies failed to demonstrate a causal relationship between uric acid and CKD, and clinical trials have had variable results. Here we suggest potential explanations for the negative clinical and genetic findings, including the role of crystalline uric acid, intracellular uric acid, and xanthine oxidase activity in uric acid-mediated kidney injury. We propose future clinical trials as well as an algorithm for treatment of hyperuricemia in patients with CKD.

20 September 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
LTLuan D. Truong
Luan D. Truong
JTJessica Trostel
Jessica Trostel
CRCarlos Roncal
Carlos Roncal
GCGabriel Cara-Fuentes
Gabriel Cara-Fuentes
MMMakoto Miyazaki
Makoto Miyazaki
FAFernando Garcia Arroyo
Fernando Garcia Arroyo
Key Points: Our study demonstrated the sole enzyme responsible for acetylcholine production, choline acetyltransferase, was expressed in podocytes. Acetylcholine decreased glomerular injury in GN by reducing inflammation and protecting endothelium. Choline acetyltransferase/acetylcholine production was induced in podocytes with drugs already available. Background: One of the most important factors modulating endothelial health is acetylcholine; and while it is associated as a cholinergic neurotransmitter, it is also expressed by non-neuronal cells. However, its role in the kidney, which does not receive cholinergic innervation, remains unknown. Methods: To determine whether acetylcholine is produced in the kidney, we used choline acetyltransferase (ChAT) (BAC)–enhanced green fluorescent protein (ChAT mice) transgenic mice in which enhanced green fluorescent protein is expressed under the control of the endogenous ChAT transcriptional regulatory elements. We then investigated the role of acetylcholine in kidney disease by inducing antiglomerular basement membrane GN (anti-GBM GN) in ChAT transgenic mice. Results: We demonstrate ChAT, the sole enzyme responsible for acetylcholine production, was expressed in glomerular podocytes and produced acetylcholine. We also show during anti-GBM GN in ChAT transgenic mice, ChAT expression was induced in the glomeruli, mainly in podocytes, and protects mice from kidney injury with marked reduction of glomerular proliferation/fibrinoid necrosis (by 71%), crescent formation (by 98%), and tubular injury (by 78%). By contrast, specific knockout of podocyte ChAT worsened the severity of the disease. The mechanism of protection included reduction of inflammation, attenuation of angiogenic factors reduction, and increase of endothelial nitric oxide synthase expression. In vitro and in vivo studies demonstrated available drugs such as cholinesterase inhibitors and ChAT inducers increased the expression of podocyte-ChAT and acetylcholine production. Conclusions: These findings suggest de novo synthesis of acetylcholine by podocytes protected against inflammation and glomerular endothelium damage in anti-GBM GN. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2024_12_05_ASN0000000000000492.mp3